[go: up one dir, main page]

RU2018120695A - Связывающие молекулы, специфичные в отношении asct2, и их применения - Google Patents

Связывающие молекулы, специфичные в отношении asct2, и их применения Download PDF

Info

Publication number
RU2018120695A
RU2018120695A RU2018120695A RU2018120695A RU2018120695A RU 2018120695 A RU2018120695 A RU 2018120695A RU 2018120695 A RU2018120695 A RU 2018120695A RU 2018120695 A RU2018120695 A RU 2018120695A RU 2018120695 A RU2018120695 A RU 2018120695A
Authority
RU
Russia
Prior art keywords
antibody
seq
binding fragment
amino acid
acid sequence
Prior art date
Application number
RU2018120695A
Other languages
English (en)
Other versions
RU2018120695A3 (ru
RU2710194C9 (ru
RU2710194C2 (ru
Inventor
Набенду ПОР
БОРРОК Мартин Дж., III
Партха ЧОВДХУРИ
Эмиль Ф. МИКЕЛОТТИ
Дэвид А. ТАЙС
Роберт Е. ХОЛЛИНГСВОРТ
Чиэнь-Ин ЧАН
Original Assignee
МЕДИММЬЮН, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by МЕДИММЬЮН, ЭлЭлСи filed Critical МЕДИММЬЮН, ЭлЭлСи
Publication of RU2018120695A publication Critical patent/RU2018120695A/ru
Publication of RU2018120695A3 publication Critical patent/RU2018120695A3/ru
Application granted granted Critical
Publication of RU2710194C2 publication Critical patent/RU2710194C2/ru
Publication of RU2710194C9 publication Critical patent/RU2710194C9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (20)

1. Антитело или его антиген-связывающий фрагмент, которые специфично связываются с эпитопом транспортного белка 2 переноса нейтральных аминокислот (ASCT2), где антитело или антиген-связывающий фрагмент содержат три определяющих комплементарность участка тяжелой цепи (HCDR) вариабельного участка тяжелой цепи (VH) и три определяющих комплементарность участка легкой цепи (LCDR) вариабельного участка легкой цепи (VL); где антитело или его антиген-связывающий фрагмент содержат HCDR1, чья аминокислотная последовательность приведена в SEQ ID NO: 10 или SEQ ID NO: 16; HCDR2 с аминокислотной последовательностью, приведенной в SEQ ID NO: 11 или SEQ ID NO: 17; HCDR3 с аминокислотной последовательностью, приведенной в SEQ ID NO: 12 или SEQ ID NO: 18; LCDR1 с аминокислотной последовательностью, приведенной в SEQ ID NO: 13 или SEQ ID NO: 19; LCDR2 с аминокислотной последовательностью, приведенной в SEQ ID NO: 14 или SEQ ID NO: 20; и LCDR3 с аминокислотной последовательностью, приведенной в SEQ ID NO: 15 или SEQ ID NO: 21.
2. Антитело или антиген-связывающий фрагмент по п. 1, где VH содержит аминокислотную последовательность, выбранную из SEQ ID NO: 1; SEQ ID NO: 3; SEQ ID NO: 5 и SEQ ID NO: 7; и где VL содержит аминокислотную последовательность, выбранную из SEQ ID NO: 2; SEQ ID NO: 4; SEQ ID NO: 6 и SEQ ID NO: 8.
3. Антитело или антиген-связывающий фрагмент по любому одному из пп. 1 или 2, где VH содержит аминокислотную последовательность, приведенную в SEQ ID NO: 5, а VL содержит аминокислотную последовательность, приведенную в SEQ ID NO: 6.
4. Антитело или антиген-связывающий фрагмент по любому одному из пп. 1 или п. 2, где VH содержит аминокислотную последовательность SEQ ID NO: 7, а VL содержит аминокислотную последовательность SEQ ID NO: 8.
5. Антитело или антиген-связывающий фрагмент по любому одному из пп. 1-4, где антитело или антиген-связывающий фрагмент содержат константный участок IgG, содержащий вставку цистеина (C) между серином (S) в положении 239 и валином (V) в положении 240.
6. Антитело или антиген-связывающий фрагмент по п. 5, где антитело содержит тяжелую цепь с аминокислотной последовательностью, приведенной в SEQ ID NO: 9.
7. Антитело или антиген-связывающий фрагмент по любому одному из пп. 1-6, где при связывании антитела с ASCT2 на клеточной поверхности антитело поглощается клеткой.
8. Антитело или антиген-связывающий фрагмент по любому одному из пп. 1-8, которые содержат константный участок легкой цепи, выбранный из группы, состоящей из константного участка каппа-цепи человека и константного участка лямбда-цепи человека.
9. Антитело или антиген-связывающий фрагмент по п. 9, где антитело содержит константный участок каппа-цепи человека, приведенный в SEQ ID NO: 26.
10. Антитело или антиген-связывающий фрагмент по любому одному из пп. 1-9, дополнительно конъюгированные с цитотоксином, выбранным из группы, состоящей из противомикробного средства, терапевтического средства, пролекарства, пептида, белка, фермента, липида, модификатора биологического ответа, фармацевтического средства, лимфокина, гетерологичного антитела, фрагмента гетерологичного антитела, детектируемой метки, полиэтиленгликоля (PEG), радиоизотопа и комбинации двух или более из любых указанных цитотоксинов.
11. Антитело или антиген-связывающий фрагмент по п. 10, которые конъюгированы с цитотоксином.
12. Антитело или антиген-связывающий фрагмент по п. 11, где цитотоксин выбирают из производного тубулизина и пирролобензодиазепина.
13. Антитело или антиген-связывающий фрагмент по п. 12, где производное тубулизина представляет собой тубулизин AZ1508.
14. Антитело или антиген-связывающий фрагмент по п. 12, где пирролобензодиазепин выбирают из SG3315 и SG3249.
15. Антитело или антиген-связывающий фрагмент по любому одному из пп. 1-14, где антитело связывается с ASCT2 человека и ASCT2 макака-крабоеда.
16. Антитело или антиген-связывающий фрагмент по любому одному из пп. 1-15, где антитело специфично не связывается с ASCT1 человека.
17. Фармацевтическая композиция, содержащая антитело или антиген-связывающий фрагмент по любому одному из пп. 1-16 и фармацевтически приемлемый носитель.
18. Полинуклеотид или комбинация полинуклеотидов, кодирующие антитело или его антиген-связывающий фрагмент по любому одному из пп. 1-16.
19. Способ получения антитела или его антиген-связывающего фрагмента по любому одному из пп. 1-16, включающий в себя культивирование хозяина, содержащего полинуклеотид по п. 18.
20. Способ лечения онкологического заболевания, характеризующегося сверхэкспрессией ASCT2 у субъекта, причем способ включает введение субъекту, нуждающемуся в лечении, эффективного количества антитела или антиген-связывающего фрагмента по любому одному из пп. 1-16 или фармацевтической композиции по п. 1.
RU2018120695A 2015-11-10 2016-11-10 Связывающие молекулы, специфичные в отношении asct2, и их применения RU2710194C9 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562253371P 2015-11-10 2015-11-10
US62/253,371 2015-11-10
US201562253774P 2015-11-11 2015-11-11
US62/253,774 2015-11-11
PCT/US2016/061219 WO2017083451A1 (en) 2015-11-10 2016-11-10 Binding molecules specific for asct2 and uses thereof

Publications (4)

Publication Number Publication Date
RU2018120695A true RU2018120695A (ru) 2019-12-16
RU2018120695A3 RU2018120695A3 (ru) 2019-12-16
RU2710194C2 RU2710194C2 (ru) 2019-12-24
RU2710194C9 RU2710194C9 (ru) 2020-09-14

Family

ID=57421946

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018120695A RU2710194C9 (ru) 2015-11-10 2016-11-10 Связывающие молекулы, специфичные в отношении asct2, и их применения

Country Status (29)

Country Link
US (2) US10829554B2 (ru)
EP (2) EP3719039B1 (ru)
JP (1) JP6898925B2 (ru)
KR (1) KR20180073675A (ru)
CN (1) CN108290949B (ru)
AU (1) AU2016352967A1 (ru)
BR (1) BR112018008983A2 (ru)
CA (1) CA3003468C (ru)
CL (1) CL2018001238A1 (ru)
CO (1) CO2018004930A2 (ru)
CY (1) CY1123525T1 (ru)
DK (1) DK3374398T3 (ru)
ES (2) ES2959663T3 (ru)
HR (1) HRP20200882T1 (ru)
HU (1) HUE050312T2 (ru)
IL (1) IL259036B (ru)
LT (1) LT3374398T (ru)
MX (1) MX2018005541A (ru)
MY (1) MY192146A (ru)
PL (1) PL3374398T3 (ru)
PT (1) PT3374398T (ru)
RS (1) RS60389B1 (ru)
RU (1) RU2710194C9 (ru)
SG (2) SG10202103712VA (ru)
SI (1) SI3374398T1 (ru)
SM (1) SMT202000285T1 (ru)
TW (1) TWI726936B (ru)
WO (1) WO2017083451A1 (ru)
ZA (1) ZA201803841B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201790404A1 (ru) 2014-09-12 2017-08-31 Зе Реджентс Оф Зе Юниверсити Оф Калифорния Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака
EP3538150A4 (en) * 2016-11-10 2020-07-08 Medimmune, LLC ASCT2-SPECIFIC BINDING MOLECULES AND USES THEREOF
US20220047715A1 (en) * 2018-09-11 2022-02-17 The Johns Hopkins University Force-dependent drug release system to enhance selective killing and minimize adverse effects in cancer treatment
BR112021011729A2 (pt) 2018-12-21 2021-11-09 Regeneron Pharma Tubulisinas e conjugados de proteína-tubulisina
EP4192511A1 (en) * 2020-08-07 2023-06-14 Fortis Therapeutics, Inc. Immunoconjugates targeting cd46 and methods of use thereof
KR20240091042A (ko) * 2021-10-29 2024-06-21 롱바이오 파마 (수조우) 컴퍼니 리미티드 분리된 항원 결합 단백질 및 이의 용도
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
EP4627096A1 (en) 2022-12-02 2025-10-08 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
EP4382120A1 (en) * 2022-12-05 2024-06-12 Institut Regional du Cancer de Montpellier Anti-slc1a4 monoclonal antibodies and uses thereof
WO2024243340A1 (en) 2023-05-23 2024-11-28 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
EP4471061A1 (en) * 2023-06-01 2024-12-04 Emergence Therapeutics AG Anti-asct2-antibodies and adcs derived therefrom
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
CN118406145B (zh) * 2024-05-29 2024-11-15 北京励和同创生物科技有限公司 一种抗磷酸化ASC_Tyr 144抗体及其应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58180487A (ja) 1982-04-16 1983-10-21 Kyowa Hakko Kogyo Co Ltd 抗生物質ｄｃ−８１およびその製造法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3587814T2 (de) 1985-03-30 1994-11-10 Marc Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
FI915411A0 (fi) 1989-05-16 1991-11-15 Scripps Research Inst Samexpression av heteromeriska receptorer.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
ES2353268T3 (es) 1999-07-02 2011-02-28 Morphosys Ag Generacion de elementos de union especifica que se unen a (poli)peptidos codificados por fragmentos de adn genomico o est.
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
WO2004005326A2 (de) 2002-07-09 2004-01-15 Morphochem Aktiengellschaft Fu Tubulysinkonjugate
EP1523493B1 (de) 2002-07-09 2013-09-04 Dömling, Alexander Neue tubulysinanaloga
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
CA2504818C (en) 2002-11-07 2013-04-23 Immunogen, Inc. Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
DE10254439A1 (de) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
US20080187954A1 (en) 2004-03-10 2008-08-07 Lonza Ltd. Method For Producing Antibodies
EP1685161A1 (en) 2004-08-30 2006-08-02 Lonza Biologics plc Affinity- plus ion exchange-chromatography for purifying antibodies
WO2006076734A2 (en) * 2005-01-14 2006-07-20 Medical College Of Georgia Research Institute Prodrugs of short-chain fatty acids and treatment methods
AU2007227224A1 (en) 2006-03-23 2007-09-27 Novartis Ag Anti-tumor cell antigen antibody therapeutics
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
FR2912314B1 (fr) 2007-02-09 2012-08-03 Geneuro Sa Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w.
WO2009012958A2 (en) 2007-07-20 2009-01-29 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysin d analogues
US8476451B2 (en) 2007-07-20 2013-07-02 The Regents Of The University Of California Tubulysin D analogues
EP2209374B1 (en) 2007-10-25 2014-12-03 Endocyte, Inc. Tubulysins and processes for preparing
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US8168586B1 (en) 2007-11-21 2012-05-01 Celera Corporation Cancer targets and uses thereof
WO2009092014A1 (en) 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of antibodies and antibody fragments by apatite chromatography
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
JP5730570B2 (ja) * 2008-07-17 2015-06-10 協和発酵キリン株式会社 抗システムａｓｃアミノ酸トランスポーター２（ａｓｃｔ２）抗体
WO2010031185A1 (en) 2008-09-19 2010-03-25 Protox Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins
JP2012508017A (ja) 2008-11-07 2012-04-05 ファブラス エルエルシー 抗ｄｌｌ４抗体及びその使用
KR20120115511A (ko) * 2010-01-15 2012-10-18 교와 핫꼬 기린 가부시키가이샤 항시스템 ａｓｃ 아미노산 트랜스포터 ２（ａｓｃｔ２） 항체
US8889880B2 (en) 2010-08-06 2014-11-18 Endocyte, Inc. Processes for preparing tubulysins
WO2013176626A1 (en) 2012-05-25 2013-11-28 National University Of Singapore Method of identifying foetal erythroblast
EP2766048B1 (en) 2012-10-12 2014-12-10 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
TW201542594A (zh) 2014-04-11 2015-11-16 Medimmune Llc 雙特異性ｈｅｒ２抗體
MA39862A (fr) 2014-04-11 2017-02-15 Lakshmaiah Gingipalli Dérivés de tubulysine
WO2015155345A1 (en) 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
AU2015243380B2 (en) * 2014-04-11 2020-05-14 Medimmune, Llc Conjugated compounds comprising cysteine-engineered antibodies
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor
EP3538150A4 (en) 2016-11-10 2020-07-08 Medimmune, LLC ASCT2-SPECIFIC BINDING MOLECULES AND USES THEREOF

Also Published As

Publication number Publication date
RS60389B1 (sr) 2020-07-31
EP3719039B1 (en) 2023-07-26
SMT202000285T1 (it) 2020-07-08
US11608375B2 (en) 2023-03-21
HK1258317A1 (zh) 2019-11-08
EP3374398B1 (en) 2020-03-18
EP3719039A1 (en) 2020-10-07
CO2018004930A2 (es) 2018-11-30
CN108290949A (zh) 2018-07-17
PT3374398T (pt) 2020-06-16
EP3374398A1 (en) 2018-09-19
CY1123525T1 (el) 2022-03-24
KR20180073675A (ko) 2018-07-02
IL259036B (en) 2020-04-30
US20210024629A1 (en) 2021-01-28
CA3003468C (en) 2024-06-18
SG11201803068YA (en) 2018-05-30
PL3374398T3 (pl) 2020-08-24
ES2796560T3 (es) 2020-11-27
WO2017083451A8 (en) 2018-02-01
US20180273617A1 (en) 2018-09-27
CA3003468A1 (en) 2017-05-18
CL2018001238A1 (es) 2018-10-12
HRP20200882T1 (hr) 2020-09-04
TW201726738A (zh) 2017-08-01
ZA201803841B (en) 2019-04-24
WO2017083451A1 (en) 2017-05-18
MX2018005541A (es) 2018-08-01
NZ743023A (en) 2021-08-27
RU2018120695A3 (ru) 2019-12-16
SI3374398T1 (sl) 2020-07-31
MY192146A (en) 2022-08-01
RU2710194C9 (ru) 2020-09-14
IL259036A (en) 2018-06-28
JP2018535674A (ja) 2018-12-06
RU2710194C2 (ru) 2019-12-24
SG10202103712VA (en) 2021-05-28
ES2959663T3 (es) 2024-02-27
US10829554B2 (en) 2020-11-10
AU2016352967A1 (en) 2018-06-21
BR112018008983A2 (pt) 2018-10-30
LT3374398T (lt) 2020-09-10
HUE050312T2 (hu) 2020-11-30
TWI726936B (zh) 2021-05-11
DK3374398T3 (da) 2020-06-08
JP6898925B2 (ja) 2021-07-07
CN108290949B (zh) 2021-12-14

Similar Documents

Publication Publication Date Title
RU2018120695A (ru) Связывающие молекулы, специфичные в отношении asct2, и их применения
JP2022177090A5 (ru)
HRP20151019T1 (hr) PROTUTIJELA PROTIV c-MET
RU2018119165A (ru) Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
AR126019A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
RU2018145852A (ru) Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение
RU2018134331A (ru) Конъюгаты антитело-лекарственное средство на основе эрибулина и способы применения
CN109843927A (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
AR069062A1 (es) Anticuerpo anti-hepcidina
HRP20191678T1 (hr) Pd-1 protutijelo, njegov fragment koji se veže na antigen, i njegova medicinska primjena
RU2019111722A (ru) Антитела против siglec-15 и способы их применения
HRP20160485T1 (hr) Anti-mezotelinska protutijela i njihova uporaba
JP2018536393A5 (ru)
RU2015144105A (ru) Антитела к гепсидину и их применения
RU2018106364A (ru) Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
RU2013125306A (ru) Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование
HRP20110334T1 (hr) PROTUTIJELA SPECIFIČNA ZA TGF-ß1
NZ628943A (en) Human antibodies to clostridium difficile toxins
ME02798B (me) Protutijela protiv dkk-1"
RU2019104980A (ru) Анти-icos антитела
RU2019139093A (ru) Фармацевтическая композиция на основе антитела к pd-l1 и ее применение
HRP20161587T1 (hr) Protutijela protiv bmp-6
RU2017137496A (ru) Средство для лечения множественной миеломы (ММ)

Legal Events

Date Code Title Description
TH4A Reissue of patent specification